Additional patients treated in LIDDS clinical study NZ-DTX-001
April 01, 2020 02:30 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announces that the dose escalation in the Phase I study NZ-DTX is proceeding according to the protocol, with additional patients being treated at a higher dose level...
LIDDS announces positive preclinical data for NanoZolid®-TLR9 agonist project
March 25, 2020 03:30 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) has performed preclinical studies using a TLR9 agonist formulated with NanoZolid® (NZ-TLR9) showing that a single NZ-TLR9 injection is reducing tumor growth and...
LIDDS will participate in Redeye’s Fight Cancer Seminar on March 10
March 05, 2020 02:30 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) - LIDDS CEO, Monica Wallter, will present the company at the Redeye Fight Cancer Seminar taking place in Stockholm on March 10, targeting both private and...
LIDDS Delårsrapport Oktober - December 2019
February 27, 2020 02:45 ET
|
LIDDS AB
OKTOBER – DECEMBER 2019 Nettoomsättningen uppgick till MSEK 0,0 (0,0)Kostnaderna uppgick till MSEK -15,1 (-4,9)Resultatet före och efter skatt uppgick till MSEK -15,1 (-4,9)Resultat per aktie uppgick...
LIDDS completes a direct share issue raising SEK 8.0 million
February 26, 2020 13:00 ET
|
LIDDS AB
The board of directors of LIDDS AB has decided to carry out a directed issue of 467,783 shares at a subscription price of SEK 17 per share. LIDDS will through the directed share issue receive proceeds...
LIDDS: Second patient treated in the Phase I study, NZ-DTX-001
February 19, 2020 02:30 ET
|
LIDDS AB
UPPSALA, SWEDEN. LIDDS AB (publ) – The National Cancer Institute in Vilnius, Lithuania, has enrolled and dosed their first patient. The aim of the phase I dose escalation clinical trial is to assess...
LIDDS: Last patient treated in Liproca® Depot open label extension study
February 11, 2020 02:30 ET
|
LIDDS AB
UPPSALA, SWEDEN. LIDDS AB (publ) - The last patient has been dosed in the voluntary open-label extension (OLE) of LPC-004. This means that all patients included in the clinical study have been dosed....
LIDDS: The United States Patent and Trademark Office has registered the LIDDS trademark NANOZOLID in the US
January 14, 2020 02:45 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) today announces that the United States Patent and Trademark Office has registered the trademark NanoZolid. LIDDS thereby has exclusive rights to the trademark for...
LIDDS: Stockpicker´s buy recommendation for 2020 picks LIDDS share as one of twelve attractive Swedish companies
January 13, 2020 09:15 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ)In a novel analysis by Stockpicker, an independent Swedish financial firm focusing on stock and fund analysis, LIDDS is listed as one of twelve interesting shares to...
LIDDS obtains novel US product patent that significantly broadens protection on NanoZolid® pharmaceuticals
January 09, 2020 02:45 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) today announces that the United States Patent and Trademark Office has approved a novel product patent on NanoZolid pharmaceutical formulations. The novel patent...